Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368055 · ClinicalTrials.gov registry record · NA
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 361
- Enrollment target
NCT01368055: Completed NA study, sponsored by University of Florida.
NCT01368055 is a NA study that has completed, run by University of Florida. The registered enrollment target is 361 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01368055, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 361 participants
- Enrollment target
Study Summary
The purpose of this trial is to give a shorter course (5 ½-6 weeks) of proton radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of proton radiation, without decreasing the chance of killing prostate cancer cells.
Interventions
- RADIATION 70 Gy/CGE
- RADIATION 72.5 Gy/CGE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2011-09 |
| Est. Completion | 2025-08 |
| Phase | NA |
What the finished NCT01368055 record still lists
NCT01368055 is an interventional study that assigns participants to a tested intervention. The registered 361 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which 70 Gy/CGE is the first listed.
NCT01368055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01368055 about?
NCT01368055 is a clinical study titled "Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer". The purpose of this trial is to give a shorter course (5 ½-6 weeks) of proton radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of proton radiation, without decreasing the chance of killing prostate cancer cells.
What is the current status of trial NCT01368055?
This trial is currently completed. It is a NA study. The enrollment target is 361 participants. The study started on 2011-09. Estimated completion is 2025-08.
What interventions are being tested in trial NCT01368055?
The interventions under investigation include: 70 Gy/CGE (RADIATION), 72.5 Gy/CGE (RADIATION).
Who is sponsoring clinical trial NCT01368055?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01368055's enrollment target sits among peer trials
361 284th of 2000 higher than 1,717 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05533697 · 361 participants · Phase 1
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia